subject area of
- Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium Journal Articles
- Canadian Cohort Expanded-Access Program of Nivolumab Plus Ipilimumab in Advanced Melanoma Journal Articles
- Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review Journal Articles
- Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors Journal Articles
- Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non–Small Cell Lung Cancer Journal Articles
- Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes Journal Articles
- FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy Journal Articles
- Immune Checkpoint Inhibitors for Patients With Advanced Non–Small-Cell Lung Cancer: A Systematic Review Journal Articles
- Immunotherapy in the Elderly Journal Articles
- Metabolomic adaptations and correlates of survival to immune checkpoint blockade Journal Articles
- Multisystem Immune-Related Adverse Events from Dual-Agent Immunotherapy Use Journal Articles
- Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer Journal Articles
- Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC Journal Articles
- Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer Journal Articles
- Nivolumab in Squamous Cell Carcinomas of the Head and Neck (SCCHN): A Real-world Outcome Study in Ontario, Canada Conferences
- Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study Journal Articles
- Pointed Progress in Second-Line Advanced Non–Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition Journal Articles
- Predictors of Immunotherapy-Induced Immune-Related Adverse Events Journal Articles
- Real-World Benefit of Nivolumab in A Canadian Non-Small-Cell Lung Cancer Cohort Journal Articles
- Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series Journal Articles
- SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma Conferences
- SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer Journal Articles
- Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors Journal Articles
- Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Journal Articles
- The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population Journal Articles
- Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline Journal Articles
- Two-year survival with nivolumab in previously treated advanced non–small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada Journal Articles
- Update on the Management of Stage III NSCLC: Navigating a Complex and Heterogeneous Stage of Disease Journal Articles
- Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients Journal Articles